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Abstract We previously demonstrated that oral application
of the recombinant single-domain antibody fragment (VHH)
clone K609, directed against Escherichia coli F4 fimbriae,
reduced E. coli-induced diarrhoea in piglets, but only at high
VHH doses. We have now shown that a large portion of the
orally applied K609 VHH is proteolytically degraded in the
stomach. Stringent selection for proteolytic stability identi-
fied seven VHHs with 7- to 138-fold increased stability after
in vitro incubation in gastric fluid. By DNA shuffling we
obtained four clones with a further 1.5- to 3-fold increased in
vitro stability. These VHHs differed by at most ten amino
acid residues from each other and K609 that were scattered
over the VHH sequence and did not overlap with predicted
protease cleavage sites. The most stable clone, K922,
retained 41% activity after incubation in gastric fluid and
90% in jejunal fluid. Oral application of K922 to piglets
confirmed its improved proteolytic stability. In addition,
K922 bound to F4 fimbriae with higher affinity and inhibited
fimbrial adhesion at lower VHH concentrations. K922 is
thus a promising candidate for prevention of piglet
diarrhoea. Furthermore, our findings could guide selection
and improvement by genetic engineering of other recombi-
nant antibody fragments for oral use.
Introduction
Enterotoxigenic Escherichia coli (ETEC) is an important
cause of diarrhoea and mortality in recently weaned piglets.
ETEC infections can be prevented by passive administra-
tion of antibodies binding to ETEC fimbriae of the F4 type,
which results in prevention of bacterial adherence to the
intestinal mucosa (Nagy and Fekete 1999). The aim of our
study is to use single-domain antibody fragments (VHHs)
for such immunotherapy (Harmsen et al. 2005). VHHs are
derived from camelid heavy chain antibodies and are
naturally devoid of light chains (Hamers-Casterman et al.
1993). They have a high physicochemical stability (Van der
Linden et al. 1999) and are well expressed in microorgan-
isms (Frenken et al. 2000). We previously isolated six F4
fimbriae binding VHHs from yeast VHH expression
libraries. One of these VHHs, K609, effectively inhibited
in vitro ETEC adhesion to the intestinal mucosa but poorly
protected piglets against ETEC infection after oral admin-
istration (Harmsen et al. 2005).
The effectiveness of oral immunotherapy is often
complicated by partial proteolytic degradation of anti-
bodies within the gastro-intestinal (GI) tract (Schmidt et al.
1989; Wiedemann et al. 1990; Yokoyama et al. 1993;
Reilly et al. 1997). Here, we have shown that this was also
the case for K609. Proteolysis of ingested proteins is
initiated by the action of pepsin in the stomach and
continued in the duodenum by the action of trypsin and
chymotrypsin. These proteases have different primary
cleavage site specificities that are dependent on particular
amino acid sequence patterns in their substrates. Specificity
is furthermore determined by the accessibility of such
putative protease cleavage sites within the folded protein
(Keil 1992). Thus, proteolysis is most efficient on flexible,
surface-exposed regions of proteins such as the antibody
hinge region (North 1989). Degradation of antibodies
therefore initially results in F(ab′)2, Fab and Fc fragments.
The F(ab′)2 and Fab fragments can retain some of their
neutralizing activity in the GI tract, which is, however, lost
upon further proteolysis of these fragments. Antibody
fragments with different variable domains differ in their
sensitivity to proteolysis (Reilly et al. 1997).
The use of recombinant antibody fragments for oral
immunotherapy opens the possibility of selection and
engineering of proteolytically stable forms. Among the
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many methods to improve the physicochemical stability of
enzymes and recombinant antibody fragments, DNA
shuffling is often used (Kurtzman et al. 2001). This
method relies on the random recombination of different
gene segments by DNA fragmentation and polymerase
chain reaction (PCR) reassembly. However, this method
has never been used for increasing proteolytic stability.
Here, we describe (1) the phage display selection of anti-F4
VHHs with significantly increased resistance to in vitro
proteolysis, (2) the further improvement in proteolytic
stability by DNA shuffling and (3) the in vivo stability of
the optimized VHH after oral application to piglets.
Materials and methods
Strains and genetic constructs
E. coli XL1-Blue (Stratagene, La Jolla, CA) was used for
routine recombinant DNA manipulation. E. coli TG1 (Stra-
tagene) was used for phage display purposes. Saccharomyces
cerevisiae SU51 (can1; his4–519; leu2–3, −112; cir+) was
used for VHH production as described previously (Van der
Vaart 2002).
Phage display selection of F4 fimbriae binding VHHs
The VHH repertoire of a llama that was previously
immunized with F4 fimbriae (Harmsen et al. 2005) was
recovered from peripheral blood lymphocytes as recently
described (Frenken et al. 2000) and separately inserted into
the PstI–HindIII cut phage display vector pUR4676 and the
PstI–BstEII cut yeast expression vector pUR4584 as
described before (Harmsen et al. 2002). pUR4584 is a
2-μm-based LEU2-marked plasmid suitable for GAL7
promoter-controlled expression of VHHs fused to the yeast
invertase signal peptide that does not encode a C-terminal
c-myc tag but is further identical to pUR4585 (Harmsen et
al. 2000). VHH clones were transferred between pUR4676
and pUR4584 using the PstI and BstEII restriction sites.
Phage display selections of clones producing VHHs
binding to F4 fimbriae were performed using a single
round of biopanning (McCafferty and Johnson 1996) using
Maxisorb immunotubes (Nunc, Roskilde, Denmark) coat-
ed with 1, 0.1 or 0.01 μg/ml F4 fimbriae.
Sequencing and sequence analysis
Single-domain antibody fragment encoding regions of
pUR4676-derived plasmids were subjected to automated
DNA sequencing as described previously (Harmsen et al.
2000). The deduced VHH amino acid sequences were
aligned according to the International ImMunoGeneTics
Information System (IMGT) (Lefranc 2004) for alignment,
numbering and complementarity-determining region
(CDR) definition of immunoglobulins. Putative protease
cleavage sites were predicted based on the VHH amino
acid sequence using a Web-based tool (http://www.
expasy.org/tools/peptidecutter) and the following cleav-
age site definitions (Keil 1992). Chymotrypsin cleaves
C-terminal to Phe, Tyr and Trp but not N-terminal to Pro
residues. Trypsin cleaves C-terminal to Arg and Lys but
not N-terminal to Pro residues. The pepsin cleavage site
was defined as it occurs above pH 2.
In vitro F4 fimbriae villous epithelium adhesion
inhibition assay
The ability of anti-F4 VHHs to inhibit binding of F4
fimbriae to isolated brush borders (BBs) was determined
using an inhibition enzyme-linked immunosorbent assay
(ELISA). BBs were isolated from the small intestine of an
F4ac-receptor-positive piglet as described previously
(Sellwood et al. 1975). The protein content of the isolated
BB preparation was determined using the Bio-Rad protein
assay (Bio-Rad, Hercules, CA). Polystyrene Polysorb 96-
well plates (Nunc) were coated with 6 mg/l BBs in 0.05 M
carbonate/bicarbonate buffer, pH 9.6. Subsequently,
100 μl 0.1 mg/l biotinylated F4-fimbriae in phosphate-
buffered saline (PBS) containing 1% ovalbumin (Sigma,
Saint Louis, MO; grade V) and 0.05% Tween 20 was pre-
incubated with a twofold dilution series of purified VHH
for 1 h at room temperature, transferred to the BB-coated
plate and incubated for another hour. Bound biotinylated
F4 fimbriae were then detected using peroxidase-con-
jugated streptavidin (Jackson Immunoresearch, West
Grove, PA) and the peroxidase substrate 3,3′,5,5′-tetra-
methylbenzidine (TMB). A control incubation without
VHH resulted in an extinction at 450 nm of 1.2. The 50%
inhibitory concentration (IC50) was calculated by inter-
polating the VHH concentration, resulting in 50% of this
extinction value.
DNA shuffling for improving proteolytic stability
A secondary phage display library of anti-F4 VHHs was
generated by DNA shuffling according to Adey et al.
(1996) using equal amounts of the K609, K712 and K719
VHH encoding inserts of pUR4584-derived plasmids that
were obtained by PCR amplification using primers BOLI5
(5′-ATTATTTTAGCGTAAAGGATGGGG-3′) and BOLI6
(5′-CCTTTTCCTTTTGGCTGGTTTTGC-3′). These shuf-
fled fragments were then inserted into phage display vector
pUR4676 using the PstI and BstEII sites. A single round of
phage display selection on immunotubes coated with
0.01 μg/ml F4 fimbriae was performed as described
above but using phage incubated in jejunal or gastric fluid
prior to selection. Based on preliminary experiments we
chose a GI fluid concentration that resulted in a decrease in
antigen binding capacity in phage ELISA to 10% of an
untreated control.
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Affinity measurements
Surface plasmon resonance study of VHH interactions with
F4 fimbriae was performed on a BIAcore 3000 instrument
(BIAcore, Uppsala, Sweden). F4 fimbriae were immobi-
lized on a BIAcore CM5 sensor chip using an amine
coupling kit (BIAcore). Then, concentration series of VHHs
were applied to the chip in 10 mM 4-2-hydroxyethyl-1-
piperazineethanesulfonic acid (HEPES)-buffered saline,
pH 7.4, [containing 3.4 mM Titriplex III, 0.15 M NaCl
and 0.05% surfactant P20 (BIAcore)] at 25°C and a flow
rate of 50 μl/min. After each measurement, residual VHH
was removed using 100 mM HCl. Association and disso-
ciation rate constants (Ka and Kd) were calculated using a
1:1 Langmuir binding model and BIAevaluation 3.0 soft-
ware (BIAcore). KD was calculated by dividing Kd by Ka.
In vitro proteolytic stability of VHHs
Gastric or jejunal fluid was derived from 4-week-old specific
pathogen-free piglets. In initial experiments (Table 1) we
used freshly prepared GI fluids from a single piglet. Later,
we pooled the jejunum content of 5 piglets and the stomach
content of 15 piglets. The pooled stomach content had a pH
of 2.8. All samples were clarified by centrifugation and
stored as aliquots at −20°C. For assays with purified
proteases we used porcine pepsin (Sigma), bovine trypsin
(Roche Applied Science, Mannheim, Germany) and bovine
chymotrypsin (Merck). Incubations with pepsin were
performed in 10 mM HCl (pH 2) and with the other two
proteases in 1 mM Tris–Cl (pH 8.0), 20 mM CaCl2.
For quantitative measurements a 2-μg amount of purified
yeast-produced VHH was incubated in 20 μl of gastric or
jejunal fluid or protease solution and in PBS (control) for 1 h
at 37°C. The reaction was stopped by the addition of 200 μl
PBS containing 1% skimmedmilk, 1 g/l Pefabloc SC (Roche
Applied Science), 1 μM pepstatin A and 100 mM Tris–Cl
(pH 8.5). The amount of functional VHH was then
determined by antigen-specific ELISA as follows: Polysty-
rene 96-well plates (Greiner, Solingen, Germany) were
coated with 5 μg/ml F4 fimbriae in 0.05 M carbonate/
bicarbonate buffer, pH 9.6. Residual sites were blocked for
2 h with 1% skimmed milk in PBS. After incubation with
serial twofold dilutions of VHHs, bound VHHs were
detected with peroxidase-conjugated rabbit anti-llama im-
munoglobulins and staining with 3,3′,5,5′ tetramethylbenzi-
dine. Antibody titres were calculated by interpolating the
VHH concentration, resulting in an extinction at 450 nm of
0.3. The percentage functional VHH remaining after prote-
olysis relative to incubation in PBS was then calculated.
For semi-quantitative measurements 1 μl of E. coli
culture supernatant containing soluble VHH was incubated
in 20 μl GI fluid and in PBS and analysed by ELISA at a
single tenfold dilution as described above. The ratio of the
extinction at 450 nm of the GI fluid sample and the PBS
control was taken as a measure for proteolytic stability.
In vivo proteolytic stability of VHHs
Ten piglets were weaned at 3 weeks of age and fed a
standard piglet feed ad libitum. Two groups of five piglets
received either yeast-produced K609 or K922 that was
purified by affinity chromatography using protein A or Ni-
NTA (Van der Vaart 2002), respectively, 1 week later. Each
piglet received 5 ml PBS containing 0.1 g CoEDTA and
0.5 mg VHH by injection into the throat. CoEDTA was
included as a non-degradable and non-absorbed tracer. The
piglets were killed 3 h later, and the stomach and duodenum
content were collected entirely, whereas the jejunum
content was collected in six to eight segments of about
1 m. The posterior small intestinal segment was defined as
the ileum. The pH of the collected stomach content was
determined. Then, proteolytic activity was stopped by
adding 0.1 volume 1MTris–Cl (pH 8.5) and 0.01 vol 1 mM
pepstatin A to gastric samples and 0.01 vol 10 g/l Pefabloc
SC to other GI samples. The samples were then clarified by
centrifugation. The amount of functional VHH in these
samples was determined by antigen-specific ELISA using
purified VHHs as a standard. The cobalt concentration was
determined by inductively coupled plasma atomic emission
spectroscopy (ISO 11885; International Organization for
Standardization; http://www.iso.ch/iso/en/). The proteolyt-
ic stability of VHHs in each segment was then calculated by
the formula VoutCinCoutVin
h i
×100 (%), where V and C represent
VHH, and cobalt concentrations in the mixture given to the
piglets (in) and in the GI contents (out). Statistical analysis
was performed using an unpaired one-sided Student’s t test.
Nucleotide sequence accession numbers
Nucleotide sequences encoding unique VHHs were sub-
mitted to the European Molecular Biology Laboratory
(EMBL) database (Fig. 1). Note that clones K609 and
K719 were isolated previously (Harmsen et al. 2005).
Results
Proteolytic susceptibility of F4 fimbriae binding
VHHs
A large fraction of six previously isolated F4 fimbriae
binding VHHs (Harmsen et al. 2005) is degraded after in
Table 1 Proteolytic stability of VHHs in gastrointestinal fluids
Clone Stability in stomach (%) Stability in jejunum (%)
K3 <1 <1
K27 <0.5 <0.5
K609 <0.1 0.3
K719 <0.1 1.3
K807 0.13 <0.1
K812 0.18 1.2
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vitro incubation in either gastric or jejunal fluid from newly
weaned piglets (Table 1). The K609 VHH was not
inactivated by incubation in 0.1 M HCl (pH 1) or in gastric
fluid that was not pH-neutralized, but which contained
pepstatin A to inhibit pepsin activity (results not shown).
This indicates that VHH inactivation in gastric fluid was not
caused by the low pH of this sample but due to proteolysis.
Isolation of F4 binding VHHs with increased
proteolytic stability by phage display
After a single round of phage display selection from a
previously immunized llama, about 50% of the individual
clones bound F4 fimbriae. After semi-quantitative measure-
ments of proteolytic stability of 721 F4-binding clones, we
selected the 12 apparently most stable clones which could
also inhibit fimbrial adhesion to the intestinal mucosa.
Sequencing of their VHH encoding region revealed that
clone K712 was isolated three times, and clone K910 was
isolated four times, resulting in seven unique clones. The
CDR3 of VHHs generally is most variable (Harmsen et al.
2000) and is directly involved in antigen binding. The
seven clones and the previously isolated clones K609 and
K719 all had similar CDR3 sequences, and their overall
sequence differed by only one to ten amino acid residues
(Fig. 1). This suggests that they have the same epitope
specificity. The seven unique VHHs were produced in
yeast and purified for further quantitative characterization.
In comparison to K609, they had a 7- to 138-fold increased
stability in gastric fluid (Fig. 2a). Some clones also showed
a small, at most twofold, increased stability in jejunal fluid
(Fig. 2b). It should be noted that we now, and in subsequent
experiments, used GI fluids pooled from several piglets
that resulted in less potent VHH inactivation than the
samples from a single piglet used previously (cf. K609 in
Table 1 and Fig. 2). Furthermore, all newly isolated clones
inhibited fimbrial adhesion to the intestinal mucosa at
lower VHH concentrations (Fig. 3c).
Improvement of proteolytic stability by DNA
shuffling
A second-generation phage display library was generated
by DNA shuffling of three VHHs: K609, K712 and K719.
For stringent selection of proteolytically stable VHHs this
library was treated with gastric or jejunal fluid prior to
Fig. 1 Multiple amino acid sequence alignment of F4 fimbriae
binding VHHs. Residue numbering and CDR definitions are
according to the IMGT numbering system (Lefranc 2004). Dots
indicate amino acid residues that are identical to the consensus
sequence. Four clones were obtained by DNA shuffling (indicated
by a “+” sign) of three parental clones (indicated by P). Predicted
protease cleavage sites are indicated in grey (trypsin), dark grey
(chymotrypsin) or by boxing (pepsin) of the residue forming the C
terminus after cleavage
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biopanning, which resulted in 161 F4-binding clones. The
four clones with the highest proteolytic stability (K905,
K916, K918 and K922) were expressed in yeast and
characterized as described in the previous section. They
had a 1.5- to 3-fold increased stability in both gastric and
jejunal fluid and inhibited fimbrial adhesion to the
intestinal mucosa more effectively than the most stable
parental clone, K712 (Fig. 2).
Clone K905 contains a non-parental alanine residue at
position 55 (Fig. 1) that presumably was introduced during
the PCR amplification step of the shuffling process. All
shuffled clones contain variable parts of the most stable
parental clone K712. Only the leucine at position 24 is
consistently present. However, this residue is lacking in
highly stable clones that were not shuffled such as K910
and K928. In a further attempt to specify residues that
determine proteolytic susceptibility, we predicted pepsin,
trypsin and chymotrypsin cleavage sites based on the
amino acid sequence of all 13 VHHs (Fig. 1). However, we
did not find a strong correlation between proteolytic
stability and absence of particular putative cleavage sites.
For example the glycine at position 11, which is predicted
to be a pepsin cleavage site, occurs in both clones that are
sensitive (K609) and relatively resistant (K928 and K922)
to incubation in gastric fluid (cf. Figs. 1 and 2). Fur-
thermore, the leucine at position 24 that was retained in all
shuffled clones, which are relatively stable, was predicted
to be a pepsin cleavage site. Only the glycine at position 93
of clone K719 could be associated with its high pepsin
sensitivity (Table 1). However, for most clones, we were
unable to identify the stabilizing mutations.
Clone K922 was selected for further analysis because of
its high overall proteolytic stability. Furthermore, K922
bound F4 fimbriae with increased affinity as compared to
its three parental clones, predominantly due to a decreased
dissociation rate constant (Table 2).
Fig. 2 In vitro proteolytic stability and adhesion inhibiting activity
of VHH domains. VHHs were incubated in gastric (a) or jejunal
(b) fluid for 1 h at 37°C, after which the percentage residual VHH
as compared to a mock-treated control was determined by ELISA.
c The VHH concentration resulting in 50% inhibition of adhesion
of F4 fimbriae to brush-border membranes was determined by
ELISA. Bars are means±standard deviation of three replicate
samples. The four clones obtained by DNA shuffling are indicated
by a “+” sign
Fig. 3 In vivo proteolytic stability of VHH fragments K609 (a) and
K922 (b) 3 h after oral application to groups of five piglets.
Individual piglets are indicated by letters with gastric pH between
parentheses. The proteolytic stability of VHHs was determined in
different GI segments and corrected for dilution effects. For some
segments stability could not be determined because a sufficient
amount of GI content could not be collected
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We compared the proteolytic stability of K609 and K922
after incubation with different concentrations of purified
pepsin, trypsin or chymotrypsin (Table 3). K609 was
substantially degraded already at the lowest pepsin
concentration, whereas about 80% remained intact at
100-fold higher concentrations of trypsin or chymotrypsin.
K922 degradation required a 100-fold higher pepsin con-
centration to reach the same level as observed with K609.
K922 was not degraded at the highest trypsin or chymo-
trypsin concentration tested. Thus, as compared to K609,
K922 has a substantially increased resistance against
degradation by pepsin and a moderately increased resis-
tance against degradation by trypsin or chymotrypsin.
Proteolytic stability after oral application to piglets
The proteolytic stability of K609 and K922 was analysed in
vivo in different segments of the piglet GI tract 3 h after
oral application. For both VHHs, degradation is already
high in the stomach (Fig. 3). VHH that has moved further
along the GI tract is not substantially further degraded or is
even degraded to a lesser extent in some piglets such as
piglets B and D (Fig. 3a). Assuming that VHH degradation
occurs predominantly in the stomach, the decreased VHH
degradation further along the GI tract could be due to a
faster stomach transit. Different piglets show considerable
variation in both VHH proteolytic stability and gastric pH,
which appears to be lower in piglets with higher VHH
degradation. However, despite this high variation in
stability, K609 is clearly more rapidly degraded in vivo
as compared to K922 (cf. Fig. 3a,b). In support of this
conclusion, the amounts of K609 and K922 within the
stomach differed significantly (P=0.043).
Discussion
We have shown that the K609 VHH is rapidly degraded
within the GI tract of piglets. The primary site of
degradation appears to be the stomach, since less func-
tional VHH is found after in vitro incubation in gastric
fluid (0.6%) as compared to jejunal fluid (18%).
Furthermore, K609 was much more susceptible to degra-
dation by pepsin than trypsin or chymotrypsin. Further-
more, 3 h after feeding K609 to piglets, functional VHH
levels were decreased to below 6% already within the
stomach and did not significantly decrease further along
the GI tract. This difference in the extent of in vivo and in
vitro proteolysis may be caused by the presence of other
proteins in feed in vivo, which compete with VHHs for
proteolysis. It is well known that digestion of specific
proteins can be reduced by the addition of a high amount
of other proteins (Wiedemann et al. 1990; Morgavi et al.
2000). The in vivo K609 stability varied considerably
between individual piglets and appeared to be dependent
on the gastric pH. This correlation is probably due to the
pH dependence of pepsin activity, which is optimal at
pH 2 (Becker and Rapp 1979), and further suggests that
cleavage by pepsin is the primary cause of K609
degradation. A large variation in gastric pH and proteo-
lytic activity between different piglets is commonly
observed (Low 1982; Schmidt et al. 1989) and can also
explain the difference in in vitro K609 stability using GI
fluids derived from different piglets (Table 1 and Fig. 2).
K609 and five other VHHs were previously isolated
from a small library of yeast-produced VHHs without
selection for stability (Harmsen et al. 2005). Here, we
isolated seven VHHs with a 7- to 138-fold increased in
vitro stability in gastric fluid by isolating a 100-fold higher
number of antigen specific clones from larger VHH
libraries using phage display that were subsequently
screened for proteolytic stability. Furthermore, we obtained
an additional, at most threefold, increased stability by DNA
shuffling. Thus, we have shown that relatively proteolyt-
ically stable VHHs can be isolated from larger libraries by
careful selections and further optimized by DNA shuffling.
These clones differed by only a few amino acids from
K609 and had highly identical CDR sequences. This
contrasts with the diversity of the six previously isolated
VHHs, of which only two VHHs belonged to the K609
CDR group (Harmsen et al. 2005). That more stringent
selection for proteolytic stability results in the selection of
clones from a single CDR group suggests that CDRs are
the primary site of proteolysis. This is in accordance with
the general view that CDRs form flexible surface-exposed
loops (Padlan 1994; Harmsen et al. 2000), which is a
structure that is more susceptible to proteolysis (North
1989).
Table 2 Kinetics of VHH interaction with F4 fimbriae
Clone Ka×10
5
(M−1 s−1)
Kd×10
−4
(s−1)
KD(nM)
K609 11 6.6 0.61
K712 18 1.9 0.11
K719 6.3 1.0 0.16
K922 18 0.8 0.04
Table 3 Proteolytic stability of K609 and K922 after incubation
with specific proteases
Protease Percentage residual VHH
(mean±standard deviation)
Type Concentration
(mg/ml)
K609 K922
Pepsin 0.1 0.08 ±0.007 21 ±1
Pepsin 0.01 0.7 ±0.1 39 ±3
Pepsin 0.001 17 ±4 94 ±7
Trypsin 0.1 76 ±5 102 ±8
Trypsin 0.01 102 ±8 98 ±11
Trypsin 0.001 104 ±19 102 ±7
Chymotrypsin 0.1 80 ±13 105 ±4
Chymotrypsin 0.01 94 ±11 101 ±12
Chymotrypsin 0.001 99 ±7 104 ±4
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However, the newly selected clones still varied con-
siderably in proteolytic stability. These clones had different
amino acid substitutions that were scattered around the
VHH sequence and not located at predicted protease
cleavage sites, indicating that increased resistance to
proteolysis was not caused by elimination of sites de-
termining primary protease specificity. A scattered pattern
of amino acid substitutions is commonly found in recom-
binant antibodies selected for improved affinity or phys-
icochemical stability (Daugherty et al. 2000; Jermutus et al.
2001; Zahnd et al. 2004). It has been reported that amino
acid substitutions outside the CDRs that result in increased
affinity can stabilize CDR loops in a conformation that is
more suitable for antigen binding (Foote and Winter 1992;
Padlan 1994; Wedemayer et al. 1997). Possibly, the higher
proteolytic stability of the newly selected VHHs is
similarly caused by reduced flexibility of CDR loops.
Such a suggestion is in accordance with earlier observa-
tions that proteolytic and thermal stability of proteins
generally are correlated because unfolded proteins expose
flexible regions that are more sensitive to proteolysis
(Arnold and Ulbrich-Hofmann 1997; Amin et al. 2004).
Furthermore, the proteolytic stabilization of certain en-
zymes by protein engineering was due to reduced flexibil-
ity of the protein region that was prone to proteolysis
(Frenken et al. 1993; Markert et al. 2001).
The high in vitro proteolytic stability of a clone obtained
by DNA shuffling, K922, was confirmed in vivo. As was
found for K609, most residual K922 degradation occurred
in the stomach of piglets with low gastric pH values, again
suggesting that proteolysis is due to pepsin activity.
However, K922 degradation is far lower than the 90%
degradation of egg antibodies that are successfully used for
treatment of piglet diarrhoea (Wiedemann et al. 1990).
Thus, the limited K922 degradation may not preclude
effective oral immunotherapy. Furthermore, K922 had a
tenfold higher affinity and inhibited fimbrial adhesion at
threefold lower VHH concentrations than K609, which
already gave limited protection (Harmsen et al. 2005).
Therefore, K922 is a promising candidate for oral immu-
notherapy of piglet diarrhoea.
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